Biofrontera Inc.
BFRI · XNASCIK 1858685fmd_0E1NCNKVFTP417GBWZD7D7P7QMManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Jun 30, 2026, 24 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 19 | 24 | 29 | 34 | 37 | 42 |
| Net interest income | (3) | (0) | (0) | (0) | – | – |
| Realized investment gains (losses) | – | – | 2 | (7) | (0) | 0 |
| Research and development | – | – | – | 0 | 2 | 4 |
| Selling, general and administrative | 18 | 37 | 35 | 39 | 34 | 38 |
| Total operating expenses | 28 | 49 | 47 | 57 | 55 | 53 |
| Operating income | (10) | (25) | (19) | (23) | (17) | (11) |
| Interest expense | 3 | 0 | 0 | 0 | – | – |
| Interest and investment income | 0 | 0 | – | 0 | 0 | – |
| Other non-operating income (expense) | (1) | (12) | 18 | 3 | (1) | 1 |
| Income before taxes | (11) | (38) | (1) | (20) | (18) | (11) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (11) | (38) | (1) | (20) | (18) | (11) |
| Net income | (11) | (38) | (1) | (20) | (18) | (11) |
| Net income to common shareholders | (11) | (38) | – | – | – | – |